Basit öğe kaydını göster

dc.contributor.authorAkarirmak Ü.
dc.contributor.authorKoçyiğit H.
dc.contributor.authorEskiyurt N.
dc.contributor.authorEsmaeilzadeh S.
dc.contributor.authorKuru O.
dc.contributor.authorYalçinkaya E.Y.
dc.contributor.authorCevik R.
dc.date.accessioned2020-06-21T09:42:51Z
dc.date.available2020-06-21T09:42:51Z
dc.date.issued2016
dc.identifier.issn1017-995X
dc.identifier.urihttps://doi.org/10.1590/S0080-623420160000500008
dc.identifier.urihttps://hdl.handle.net/20.500.12712/5199
dc.descriptionPubMed: 27524671en_US
dc.description.abstractObjective: In our study, we aimed to evaluate the influence of training on compliance and persistence with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis patients. Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 ± 7.2 years) were included in this national, multicenter, prospective non-interventional observational cohort registry study. Patients were randomized into training (n = 492, 50.3%, mean age: 63.4 ± 7.2 years) and control (n = 487, 49.7%, mean age: 63.0 ± 7.1 years) groups. Patients in each intervention group were given weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%, respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse events. Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days of duration during the 12-month follow-up period. The mean compliance in the compliant and fully compliant group remained at an average of 86.6%. No significant difference was detected between the training and control groups in terms of compliance and persistence. Significantly longer persistence (360.0 ± 89.0 vs. 345.0 ± 108.0 days; p = 0.035), higher percentage of persistent patients (83.4% vs. 74.2%; p = 0.012) and higher compliance rates (88.8% vs. 83.3%; p = 0.002) were noted in monthly regimen patients in comparison to those given weekly regimen. © 2016 Turkish Association of Orthopaedics and Traumatology.en_US
dc.language.isoengen_US
dc.publisherTurkish Association of Orthopaedics and Traumatologyen_US
dc.relation.isversionof10.1590/S0080-623420160000500008en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBisphosphonateen_US
dc.subjectComplianceen_US
dc.subjectDosing regimenen_US
dc.subjectOsteoporosisen_US
dc.subjectPersistenceen_US
dc.subjectTrainingen_US
dc.titleInfluence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis [2]en_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume50en_US
dc.identifier.issue4en_US
dc.identifier.startpage592en_US
dc.identifier.endpage599en_US
dc.relation.journalActa Orthopaedica et Traumatologica Turcicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster